- Home
- OBE vs AVXL Comparison
OBE vs AVXL Comparison
Compare OBE & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- AVXL
- Stock Information
- Founded
- OBE 1979
- AVXL 2004
- Country
- OBE Canada
- AVXL United States
- Employees
- OBE N/A
- AVXL N/A
- Industry
- OBE Oil & Gas Production
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OBE Energy
- AVXL Health Care
- Exchange
- OBE Nasdaq
- AVXL Nasdaq
- Market Cap
- OBE 349.1M
- AVXL 794.0M
- IPO Year
- OBE N/A
- AVXL N/A
- Fundamental
- Price
- OBE $5.65
- AVXL $9.32
- Analyst Decision
- OBE Buy
- AVXL Strong Buy
- Analyst Count
- OBE 2
- AVXL 2
- Target Price
- OBE $11.50
- AVXL $44.00
- AVG Volume (30 Days)
- OBE 403.8K
- AVXL 927.5K
- Earning Date
- OBE 08-13-2025
- AVXL 08-05-2025
- Dividend Yield
- OBE N/A
- AVXL N/A
- EPS Growth
- OBE N/A
- AVXL N/A
- EPS
- OBE N/A
- AVXL N/A
- Revenue
- OBE $525,689,636.00
- AVXL N/A
- Revenue This Year
- OBE N/A
- AVXL N/A
- Revenue Next Year
- OBE $8.69
- AVXL N/A
- P/E Ratio
- OBE N/A
- AVXL N/A
- Revenue Growth
- OBE 15.98
- AVXL N/A
- 52 Week Low
- OBE $3.88
- AVXL $4.00
- 52 Week High
- OBE $7.87
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- OBE 53.89
- AVXL 60.62
- Support Level
- OBE $5.42
- AVXL $9.09
- Resistance Level
- OBE $5.60
- AVXL $9.78
- Average True Range (ATR)
- OBE 0.22
- AVXL 0.41
- MACD
- OBE -0.05
- AVXL 0.09
- Stochastic Oscillator
- OBE 22.67
- AVXL 71.58
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.